Earlam R
Royal London Hospital, Whitechapel, London.
Ann R Coll Surg Engl. 1991 Jan;73(1):8-12.
The objective of the trial was to determine whether there was any difference in survival rates after operable cases of squamous cell carcinoma of the oesophagus were treated by radiotherapy or surgery. It was designed as a prospective, randomised, multicentre trial in the United Kingdom, after staging as potentially operable, and it was planned to enter 100 patients per annum for 4 years, with a minimum follow-up of 5 years, after pre-entry staging of patients under 75 years of age by barium swallow, chest radiographs, oesophagoscopy, biopsy, bronchoscopy and CT scanning. The protocol was published in July 1986; the trial started in January 1987 and was stopped in June 1988 when only 31 patients from 16 centres were entered, although 30 centres had ethical committees' approval and were willing to start the trial. Interventions were to be as follows: 1. Surgery. According to the practice of that particular surgeon and classified as (a) curative resection if the surgeon considered that no macroscopic tumour was left behind, and (b) palliative if incompletely resected. 2. Radiotherapy. (a) Prescribed minimum corrected tumour dose of 5000 cGy with daily dose of 250 cGy in 20 fractions over 4 weeks. (b) Prescribed minimum corrected tumour dose of 6000 cGy with daily dose of 200 cGy in 30 fractions over 6 weeks. The endpoint was to be survival at 1, 2 and 5 years. The trial was discontinued after 18 months because of lack of recruitment and thus the question whether operable squamous cell cancer of the oesophagus, staged before treatment with CT scanning, is to be treated by radiotherapy or surgical resection remains unanswered. It is unlikely that a phase III trial will ever have sufficient support from surgeons to find the answer.
该试验的目的是确定可手术的食管鳞状细胞癌患者接受放射治疗或手术治疗后的生存率是否存在差异。这是一项在英国进行的前瞻性、随机、多中心试验,患者需经分期为潜在可手术,计划每年纳入100名患者,共4年,对75岁以下患者在入组前通过吞钡、胸部X光片、食管镜检查、活检、支气管镜检查和CT扫描进行分期,最低随访5年。该方案于1986年7月公布;试验于1987年1月开始,1988年6月停止,当时仅16个中心的31名患者入组,尽管有30个中心获得伦理委员会批准并愿意开展试验。干预措施如下:1. 手术。根据该特定外科医生的操作方法,分为(a)根治性切除,如果外科医生认为没有肉眼可见的肿瘤残留,以及(b)姑息性切除,如果切除不完全。2. 放射治疗。(a)规定的最小校正肿瘤剂量为5000厘戈瑞,每日剂量250厘戈瑞,分20次在4周内完成。(b)规定的最小校正肿瘤剂量为6000厘戈瑞,每日剂量200厘戈瑞,分30次在6周内完成。终点指标为1年、2年和5年生存率。由于缺乏入组患者,该试验在18个月后停止,因此,在治疗前通过CT扫描分期的可手术食管鳞状细胞癌是应接受放射治疗还是手术切除的问题仍未得到解答。一项III期试验不太可能获得外科医生的足够支持来找到答案。